Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
William M. Hart, MD, Patricia Doerr, MD, Yuxiao Qian, MD, and Peggy M. McNaull, MD
When errors happen, too often clinicians are at odds with each other about how to respond to a patient or a patient’s loved ones after that patient suffers harm.
AMA J Ethics. 2020;22(4):E298-304. doi:
10.1001/amajethics.2020.298.
Two pediatric cases highlight risks of prolonging anesthetic exposure for training purposes and prompt questions about influences of surgical training on outcomes.
AMA J Ethics. 2020;22(4):E267-275. doi:
10.1001/amajethics.2020.267.